Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Kindred Biosciences files $150M mixed securities shelf  17:15
01/15/21
01/15
17:15
01/15/21
17:15
KIN

Kindred Biosciences

$4.93 /

-0.06 (-1.20%)

 
ShowHide Related Items >><<
KIN Kindred Biosciences
$4.93 /

-0.06 (-1.20%)

KIN Kindred Biosciences
$4.93 /

-0.06 (-1.20%)

12/24/20 Barclays
Kindred atopic dermatitis portfolio could net $130M in sales, says Barclays
12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
KIN Kindred Biosciences
$4.93 /

-0.06 (-1.20%)

Over a week ago
Recommendations
Kindred atopic dermatitis portfolio could net $130M in sales, says Barclays » 06:52
12/24/20
12/24
06:52
12/24/20
06:52
KIN

Kindred Biosciences

$4.53 /

-0.16 (-3.41%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad continues to see value in Kindred Biosciences' pipeline, especially within its canine atopic dermatitis programs. Kindred could realize total peak sales of $130M in its atopic dermatitis portfolio, Prasad tells investors in a research note. Prasad keeps an Overweight rating on Kindred Biosciences with a $10 price target. He believes the company's new strategy is showing "positive early signs."

ShowHide Related Items >><<
KIN Kindred Biosciences
$4.53 /

-0.16 (-3.41%)

KIN Kindred Biosciences
$4.53 /

-0.16 (-3.41%)

12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
KIN Kindred Biosciences
$4.53 /

-0.16 (-3.41%)

Hot Stocks
Kindred begins pivotal efficacy study for tirnovetmab » 08:35
12/22/20
12/22
08:35
12/22/20
08:35
KIN

Kindred Biosciences

$4.10 /

-0.04 (-0.97%)

Kindred Biosciences…

Kindred Biosciences announced that it has initiated the pivotal efficacy study for tirnovetmab, or KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin, or IL-31 for the treatment of atopic dermatitis in dogs. Atopic dermatitis is the most common reason owners take their dog to the veterinarian, and is estimated to affect 10 - 15% of dogs worldwide1. The current market size is close to $900 million annually and growing. Other programs in development for atopic dermatitis include KIND-032, a fully caninized monoclonal antibody targeting IL-4R. A second pilot study to further assess dosing commenced in the third quarter of 2020.

ShowHide Related Items >><<
KIN Kindred Biosciences
$4.10 /

-0.04 (-0.97%)

KIN Kindred Biosciences
$4.10 /

-0.04 (-0.97%)

12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
KIN Kindred Biosciences
$4.10 /

-0.04 (-0.97%)

Hot Stocks
Kindred Biosciences announces 'positive' results from anti-TNFalpha antibody study » 08:34
12/21/20
12/21
08:34
12/21/20
08:34
KIN

Kindred Biosciences

$4.15 /

+0.15 (+3.75%)

Kindred Biosciences…

Kindred Biosciences announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha for canine inflammatory bowel disease. The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 10 dogs diagnosed with IBD to assess the efficacy and safety of KindredBio's anti-TNFalpha antibody over a 4-week treatment period. The primary effectiveness variable for this exploratory study was reduction in Canine Inflammatory Bowel Disease Activity Index score, which was assessed at Screening and Days 0, 7, 14, 21 and 28. Complete remission, defined as greater than or equal to 75% reduction in average post-dose CIBDAI score from baseline, was achieved in 75% of the anti-TNFalpha group compared to 17% in the placebo group. The treatment effect was early-onset and durable. At Day 7, the first post-dose visit, 75% of the anti-TNFalpha treated dogs showed greater than or equal to 75% reduction of CIBDAI score from baseline, compared to 17% in the placebo group. Furthermore, 50% of the anti-TNFalpha treated dogs achieved and maintained 100% reduction of CIBDAI score from baseline throughout all post-dose visits, whereas none in the placebo group achieved the same result.

ShowHide Related Items >><<
KIN Kindred Biosciences
$4.15 /

+0.15 (+3.75%)

KIN Kindred Biosciences
$4.15 /

+0.15 (+3.75%)

12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
KIN Kindred Biosciences
$4.15 /

+0.15 (+3.75%)

Over a month ago
Recommendations
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners » 11:15
12/18/20
12/18
11:15
12/18/20
11:15
KIN

Kindred Biosciences

$4.14 /

+0.14 (+3.50%)

, ELAN

Elanco

$30.37 /

-0.1 (-0.33%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor lowered the firm's price target on Kindred Biosciences (KIN) to $9.25 from $10.25 as he lowered his valuation for KIND-030 based on the terms disclosed as part of the company's agreement with Elanco (ELAN). Haynor, who said he was "relatively unimpressed" with the overall terms of the deal given the lack of clarity on the sales milestones, argues that "Elanco essentially has purchased a call option on KIND-030" for $0.5M. He keeps a Buy rating on Kindred shares.

ShowHide Related Items >><<
KIN Kindred Biosciences
$4.14 /

+0.14 (+3.50%)

ELAN Elanco
$30.37 /

-0.1 (-0.33%)

KIN Kindred Biosciences
$4.14 /

+0.14 (+3.50%)

12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
ELAN Elanco
$30.37 /

-0.1 (-0.33%)

12/09/20 Argus
Elanco cut to Hold at Argus on margin pressure from Bayer unit deal
12/09/20 Argus
Elanco downgraded to Hold from Buy at Argus
11/23/20 Morgan Stanley
Elanco price target raised to $41 from $31 at Morgan Stanley
KIN Kindred Biosciences
$4.14 /

+0.14 (+3.50%)

ELAN Elanco
$30.37 /

-0.1 (-0.33%)

  • 01
    Dec
  • 23
    Jan
ELAN Elanco
$30.37 /

-0.1 (-0.33%)

ELAN Elanco
$30.37 /

-0.1 (-0.33%)

ELAN Elanco
$30.37 /

-0.1 (-0.33%)

Recommendations
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street » 09:09
12/14/20
12/14
09:09
12/14/20
09:09
KIN

Kindred Biosciences

$3.91 /

+0.01 (+0.26%)

, ELAN

Elanco

$28.64 /

-0.155 (-0.54%)

Lake Street analyst…

Lake Street analyst Brooks O'Neil argues that the partnership deal Kindred Biosciences (KIN) announced on Friday with Elanco (ELAN) to commercialize KIND-030 is "a terrific arrangement" that sets Kindred up "in about the best way imaginable to continue to create real value for investors." He sees Elanco and Kindred taking the initial steps to explore the potential of "a much more consequential partnership" related to atopic dermatitis, unless "someone else steps up big- time soon," added O'Neil, who keeps a Buy rating and $12 price target on Kindred shares.

ShowHide Related Items >><<
KIN Kindred Biosciences
$3.91 /

+0.01 (+0.26%)

ELAN Elanco
$28.64 /

-0.155 (-0.54%)

KIN Kindred Biosciences
$3.91 /

+0.01 (+0.26%)

12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
ELAN Elanco
$28.64 /

-0.155 (-0.54%)

12/09/20 Argus
Elanco cut to Hold at Argus on margin pressure from Bayer unit deal
12/09/20 Argus
Elanco downgraded to Hold from Buy at Argus
11/23/20 Morgan Stanley
Elanco price target raised to $41 from $31 at Morgan Stanley
11/17/20 Citi
Citi boosts Elanco target to $35, opens 'positive catalyst watch'
KIN Kindred Biosciences
$3.91 /

+0.01 (+0.26%)

ELAN Elanco
$28.64 /

-0.155 (-0.54%)

  • 01
    Dec
  • 23
    Jan
ELAN Elanco
$28.64 /

-0.155 (-0.54%)

ELAN Elanco
$28.64 /

-0.155 (-0.54%)

ELAN Elanco
$28.64 /

-0.155 (-0.54%)

Hot Stocks
Kindred Biosciences: Elanco granted exclusive global rights to KIND-030 » 08:05
12/11/20
12/11
08:05
12/11/20
08:05
KIN

Kindred Biosciences

$3.87 /

+0.155 (+4.17%)

, ELAN

Elanco

$28.80 /

-0.12 (-0.41%)

Kindred Biosciences (KIN)…

Kindred Biosciences (KIN) announced an agreement granting Elanco Animal Health (ELAN) exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. As part of the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal antibody products. Under the terms of the agreement, KindredBio will receive an upfront payment of $500,000, development milestone payments of up to $16M upon achievement of certain development, regulatory and manufacturing targets, and sales milestones in an aggregate amount of up to $94M payable throughout the term of the agreement. Furthermore, royalty payments are to range from the low to high teens. The agreement specifies that KindredBio will supply the licensed product to Elanco, and that Elanco will conduct the necessary regulatory activities to achieve approvals in Europe and other key international markets.

ShowHide Related Items >><<
KIN Kindred Biosciences
$3.87 /

+0.155 (+4.17%)

ELAN Elanco
$28.80 /

-0.12 (-0.41%)

KIN Kindred Biosciences
$3.87 /

+0.155 (+4.17%)

12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
ELAN Elanco
$28.80 /

-0.12 (-0.41%)

12/09/20 Argus
Elanco cut to Hold at Argus on margin pressure from Bayer unit deal
12/09/20 Argus
Elanco downgraded to Hold from Buy at Argus
11/23/20 Morgan Stanley
Elanco price target raised to $41 from $31 at Morgan Stanley
11/17/20 Citi
Citi boosts Elanco target to $35, opens 'positive catalyst watch'
KIN Kindred Biosciences
$3.87 /

+0.155 (+4.17%)

ELAN Elanco
$28.80 /

-0.12 (-0.41%)

  • 01
    Dec
  • 23
    Jan
ELAN Elanco
$28.80 /

-0.12 (-0.41%)

ELAN Elanco
$28.80 /

-0.12 (-0.41%)

ELAN Elanco
$28.80 /

-0.12 (-0.41%)

Recommendations
Kindred price target lowered to $10.25 from $12.50 at Alliance Global » 07:55
12/01/20
12/01
07:55
12/01/20
07:55
KIN

Kindred Biosciences

$3.88 /

+ (+0.00%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor lowered the firm's price target on Kindred Biosciences to $10.25 from $12.50 and keeps a Buy rating on the shares after the company suspended its feline recombinant erythropoietin epoCat program in cats with non-regenerative anemia. The analyst views the program suspension as a disappointing development as he believes feline non-regenerative anemia could represent a far larger market than commonly believed. However, Kindred maintains backup programs in recombinant erythropoietin, which could be rekindled following the company's pursuit of canine atopic dermatitis, Haynor tells investors in a research note after speaking with management.

ShowHide Related Items >><<
KIN Kindred Biosciences
$3.88 /

+ (+0.00%)

KIN Kindred Biosciences
$3.88 /

+ (+0.00%)

07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
KIN Kindred Biosciences
$3.88 /

+ (+0.00%)

Conference/Events
Kindred Biosciences participates in a conference call with Cantor Fitzgerald » 13:25
11/30/20
11/30
13:25
11/30/20
13:25
KIN

Kindred Biosciences

$3.96 /

+0.08 (+2.06%)

Conference call with…

Conference call with management will be held on November 30 at 2 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KIN Kindred Biosciences
$3.96 /

+0.08 (+2.06%)

KIN Kindred Biosciences
$3.96 /

+0.08 (+2.06%)

07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
KIN Kindred Biosciences
$3.96 /

+0.08 (+2.06%)

Conference/Events
Kindred Biosciences participates in a conference call with Cantor Fitzgerald » 04:55
11/30/20
11/30
04:55
11/30/20
04:55
KIN

Kindred Biosciences

$3.91 /

-0.09 (-2.25%)

Conference call with…

Conference call with management will be held on November 30 at 2 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KIN Kindred Biosciences
$3.91 /

-0.09 (-2.25%)

KIN Kindred Biosciences
$3.91 /

-0.09 (-2.25%)

07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
KIN Kindred Biosciences
$3.91 /

-0.09 (-2.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.